Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Sapien Valve Keeps Delivering in Jobs for Which It Was Not Designed

We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement.

válvula Sapien en posición pulmonar

Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has accumulated and lead to papers being published.

The acute outcome of pulmonary valve replacement with the Sapien valve is excellent in all types of right ventricular outflow tract, although more cases and longer follow-up are still needed.

There are limited papers on pulmonary valve replacement with Sapien XT or Sapien 3.

Data were collected retrospectively and included in a large multicenter registry of patients who received the XT or S3 as pulmonary valve replacement. Patient and procedure characteristics were analyzed, and so were the short term results, according to the type of right ventricular outflow tract anatomy.


Read also: Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed.


Analysis included 774 patients: 397 (51%) with a native or patched outflow tract, 183 (24%) with a conduit, and 194 (25%) with a bioprosthetic valve.

Sapien 3 was used in 78% of patients, and the remainder received the XT model. Most also received the valve with the biggest diameter (29 mm).

Adverse events were reported in 10% of the population, with no difference between outflow tract anatomy.

About 14 patients underwent emergency surgery, and 9 had a second valve implanted. In 1.7% of cases tricuspid valve injury was documented, and 1.3% of patients had new moderate to severe pulmonary regurgitation not present before implantation.


Read also: Balloon-Expandable Valve Outdoes Itself.


The vast majority of patients was discharged with an excellent valve function, but 8.5% had moderate or greater pulmonary regurgitation or a >40 mmHg gradient.

Median follow-up was 12 months. During follow-up, about 9 patients were diagnosed with endocarditis and 17 underwent surgery or received a new transcatheter replacement.

Conclusion

The short term results for balloon-expandable valve implantation as pulmonary valve replacement are very good in all types of right ventricle outflow tract anatomy.

j-jacc-2020-10-041free

Original Title: Transcatheter Pulmonary Valve Replacement With the Sapien Prosthesis.

Reference: Shabana Shahanavaz et al. J Am Coll Cardiol 2020;76:2847–58.  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

The Ten Commandments in Adult Congenital Heart Disease

Adult congenital heart disease is a life-long condition that requires appropriate follow-up by experts. Said follow-up is paramount to diagnosing specific and highly variable...

Intervention in Congenital Heart Disease

Watch again our Webinar on Intervention in Congenital Heart Disease on our Youtube channel. What things will I learn if I watch this video? 03:28 -...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...